Profile of:

Antoni Chan


Antoni Chan is Consultant Rheumatologist and Associate Medical Director at the Royal Berkshire NHS Foundation Trust. He is the Trust and Berkshire West ICP clinical lead for Outpatient Transformation. He leads the Spondyloarthritis (Axial SpA and Psoriatic Arthritis) service in his Trust. He completed his PhD in Oxford under the supervision of Professors Paul Bowness and Andrew McMichael. His PhD was on the role and function of Natural Killer (NK) cells and receptors in Spondyloarthritis. He is Primary Investigator (PI) for numerous clinical trials. His team was awarded the National Axial Spondyloarthritis Society (NASS) Aspiring to Excellence Award in 2019. In 2018 he received the Patient Choice Award for Best Care by a Rheumatologist from the NASS. He has presented in Parliament to the All-Party Parliamentary Group (APPG) on improving standards of care in Spondyloarthritis. In 2017, he set up the Berkshire West Integrated Pain Assessment and Spinal Service which was recognised by the British Society for Rheumatology with a Best Practice Award. He was elected as Trustee of NASS in 2020. Twitter @synovialjoints

Full name: Antoni Chan

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 15

Ankylosing Spondylitis Best Practice (2021)
https://bestpractice.bmj.com/topics/en-gb/366

Tele clinics in rheumatology introduced during the first lockdown phase of the COVID-19 pandemic of 2020 (2020)
https://www.rcpjournals.org/content/futurehosp/early/2020/12/23/fhj.2020-0093

Virtual or Face to Face in the Post COVID-19 world (2020)
https://www.emg-health.com/omnipresent/virtual-or-face-to-face-in-the-post-covid-19-world/

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)
https://pubmed.ncbi.nlm.nih.gov/32793854/

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives (2020)
https://pubmed.ncbi.nlm.nih.gov/33273869/

Myopericarditis and myositis in a patient with COVID-19: a case report (2020)
https://pubmed.ncbi.nlm.nih.gov/33442587/

Real world experience of apremilast in treating psoriatic arthritis patients with comorbidities. (2019)
https://www.emjreviews.com/rheumatology/article/real-world-experience-of-apremilast-in-treating-psoriatic-arthritis-patients-with-comorbidities/

Implementing and delivering a successful biosimilar switch programme – the Berkshire West experience (2019)
https://pubmed.ncbi.nlm.nih.gov/31363522/

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis (2016)
https://pubmed.ncbi.nlm.nih.gov/26130142/

KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis (2013)
https://pubmed.ncbi.nlm.nih.gov/23440420/

Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis (2011)
https://pubmed.ncbi.nlm.nih.gov/21248258/

Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells (2008)
https://pubmed.ncbi.nlm.nih.gov/18311795/

Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide (2007)
https://pubmed.ncbi.nlm.nih.gov/17407096/

CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts (2007)
https://pubmed.ncbi.nlm.nih.gov/17579025/

Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis (2005)
https://pubmed.ncbi.nlm.nih.gov/16255049/